Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)

  • Beata Jagielska Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Andrzej Czubek Chamber of Commerce "Polish Medicine"
  • Konrad Talasiewicz Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw,
  • Adam Twarowski Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Piotr Rutkowski Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Maciej Krzakowski Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Bianka Saetre Phoenix Biomolecular Engineering Foundation,
  • Marek Malecki 6Genomics Laboratories, Phoenix Biomolecular Engineering Foundation
Keywords: breast cancer, trastuzumab, Herceptin, radiotherapy, chemotherapy, immunotherapy, hormonal therapy, adjuvant therapy, human epidermal growth factor receptor-2, estrogen receptor, progesterone receptor, overall survival, disease-free survival


Abstract: In patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising.



Download data is not yet available.



National Registry of Cancer, Poland. Epidemiology. Statistics. Available:

Dz.U. 2004 nr 210 poz. 2135 Ustawa z dnia 27

sierpnia 2004 r. o świadczeniachopiekizdrowotnej finansowanych ze środkówpublicznych (in Polish). Available: DU20042102135

Polish National Drug Progam. Available: http://www.

Review of the available evidence on Trastuzumab for Inclusion in the WHO Essential Medicines List as an anti-neoplastic agent Union for International Cancer Control Route de Frontenex, 62 1207 Geneva Switzerland Dana-Farber Cancer Institute Center for Global Cancer Medicine 450 Brookline Avenue, Boston, MA 02215.

BonifaziM ,Franchi M , Rossi M et al.Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinicalpractice.Breast 2014;23:573-578.

Gianni L , Dafni U , Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of arandomised controlled trial. The Lancet Oncology; Vol. 12,3:236-244.

Edith A. Perez, Edward H. Romond, Vera J. Suman et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABPB-31. J ClinOncol. 2014;32(33).

Perez E ., Romond E ., Suman V . et al. Trastuzumab plus adjuvant chemotherapy for humanepidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Br J Cancer. 2012;3;106(1).

Webster RM , Abraham J , Palaniappan N et al. Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J cancer 2012;3:106(1):32-8.

Dennis S,Wolfgang E, Nicholas R et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011;365:1273-1283.

Early Breast Cancer Trialists' Collaborative Group.

Polychemotherapy for early breast cancer: an overview

of the randomised trials. Lancet 1998;352:930-94.

Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl CancerInst 2008;100:14-20.

Qin Y-Y, Li H, Guo X-J et al. Adjuvant Chemotherapy, with or without Taxanes, in Early orOperable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients. PLoSONE 6(11): e26946.

Piccart-Gebhart M, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.

Romond E, Perez E, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.

Smith I, Procter M, Gelber RD et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer: a randomised controlled trial. Lancet2007;369:29-36.

Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, withor without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J ClinOncol, 2005;23:7811-7819.

Breast cancer in young women. Nat Rev ClinOncol. 2012;26;9(8):460-70.

Borg M. Breast- conserving therapy in young women with invasive carcinoma of the breast. Journal of Medical Imaging and Radiation Oncology 2004;48(3):376-382.

Assi H. A., Khoury K. E., Dbouk H. et al. Epidemiology and prognosis of breast cancer inyoung women. Journal of Thoracic Disease, 5(Suppl 1), S2–S8.

Wolff AC, Hammond EH, Hicks DG, Dowsett M, McShane LM, Allison KH. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline Update. DOI: 10.1200/JCO.2013.50.9984 Journal of Clinical Oncology 31, no. 31 (November 2013) 3997-4013.

Research Article